France HTA Guides
Reference guides to the key procedures and requirements for pharmaceutical assessment and market access in France.
Transparency Dossier: The French HTA dossier for HAS assessment
The Transparency Dossier (Dossier de transparence) is the manufacturer's submission for the assessment of a medicine by the Transparency Committee (Commission de la Transparence, CT) of the Haute Autorité de Santé (HAS). It brings together the medical context, unmet medical need, relevant comparators, clinical evidence, the medicine's place in the therapeutic strategy and the target population. These elements provide an important basis for the assessment of Service médical rendu (SMR) and Amélioration du service médical rendu (ASMR).
HAS submission: Pharmaceutical assessment and reimbursement in France
The HAS submission (soumission HAS) is a central step in the assessment of a medicine for standard reimbursement in France. The Transparency Committee (Commission de la Transparence, CT) of the Haute Autorité de Santé (HAS) assesses, in particular, the medical benefit (Service médical rendu, SMR), the therapeutic improvement over existing alternatives (Amélioration du service médical rendu, ASMR), and the target population relevant for reimbursement. This assessment is distinct from the regulatory benefit-risk assessment performed as part of the marketing authorisation process.